Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across immuno-oncology and regenerative medicine. The company announced the launch of Echo-T, Echo-Cardio and Echo-Endothelial at its Mont-Saint-Guibert site in Belgium, positioning the technologies as a major expansion of its existing allogeneic cell therapy capabilities.
The new platforms build on the company’s Echo-NK system for natural killer cells and draw on Cellistic’s EMA-certified and FDA- and PMDA-compliant manufacturing infrastructure. The company said the expanded portfolio is intended to offer scalable, reproducible solutions for a broader range of immune and regenerative cell types.
Gustavo Mahler, CEO of Cellistic, said: “The 2025 launch of the Echo-NK manufacturing platform marked a significant advancement in cell therapy manufacturing.”
Mahler added: “Building on this foundation and more than 15 years of experience in iPSC-derived cell therapy process development and GMP manufacturing, our team has developed three platforms designed to overcome the limitations of current cell therapy approaches. These off-the-shelf allogeneic cell therapies are a cost-effective way of ensuring more patients have access to these life-changing treatment options.”
The Echo-T platform is designed to address the scalability and variability challenges of autologous T-cell therapies by delivering iPSC-derived αβ T cells or Tregs with a defined phenotype and predictable immune function.
Echo-Cardio provides iPSC-derived cardiomyocytes intended to support cardiac regenerative programmes that require high biological fidelity. Echo-Endothelial offers iPSC-derived endothelial cells to support therapies targeting vascular biology, inflammation and the tumour microenvironment.
Mahler said: “Cellistic was created to make iPSC-based cell therapies mainstream. The addition of the new Cellistic Echo platforms reflects that mission and demonstrates that our platforms, technologies, capabilities and expertise are ready to supply the next generation of cell therapies.”
The platforms expand the company’s Pulse and Echo portfolios and are already being used in multiple development programmes, including those nearing IND submission.
